Pomanda estimates the enterprise value of NEWHAVEN PHARMACIES LIMITED at £650.8k based on a Turnover of £1.9m and 0.35x industry multiple (adjusted for size and gross margin).
newhaven pharmacies limitedEstimated Valuation
£956.3k
Pomanda estimates the enterprise value of NEWHAVEN PHARMACIES LIMITED at £956.3k based on an EBITDA of £246.5k and a 3.88x industry multiple (adjusted for size and gross margin).
newhaven pharmacies limitedEstimated Valuation
£1.6m
Pomanda estimates the enterprise value of NEWHAVEN PHARMACIES LIMITED at £1.6m based on Net Assets of £809.9k and 1.98x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Newhaven Pharmacies LimitedOverview
Newhaven Pharmacies Limited is a live company located in london, EC1V 4LY with a Companies House number of 00696374. It operates in the dispensing chemist in specialised stores sector, SIC Code 47730. Founded in June 1961, it's largest shareholder is
allcures plc
with a 100% stake. Newhaven Pharmacies Limited is a mature,
small sized company, Pomanda has estimated its turnover at
£1.9m with
healthy
growth in recent years.
Pomanda's financial health check has awarded Newhaven Pharmacies Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating4.5out of 5
4 Strong
3 Regular
5 Weak
Size
annual sales of £1.9m, make it smaller than the average company (£13.6m)
£1.9m - Newhaven Pharmacies Limited
£13.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 4%, show it is growing at a slower rate (7.7%)
4% - Newhaven Pharmacies Limited
7.7% - Industry AVG
Production
with a gross margin of 31.5%, this company has a comparable cost of product (31.5%)
31.5% - Newhaven Pharmacies Limited
31.5% - Industry AVG
Profitability
an operating margin of 13.3% make it more profitable than the average company (2.2%)
13.3% - Newhaven Pharmacies Limited
2.2% - Industry AVG
Employees
with 11 employees, this is below the industry average (72)
11 - Newhaven Pharmacies Limited
72 - Industry AVG
Pay Structure
on an average salary of £29k, the company has an equivalent pay structure (£29k)
£29k - Newhaven Pharmacies Limited
£29k - Industry AVG
Efficiency
resulting in sales per employee of £168.4k, this is equally as efficient (£155.6k)
£168.4k - Newhaven Pharmacies Limited
£155.6k - Industry AVG
Debtor Days
it gets paid by customers after 21 days, this is earlier than average (28 days)
21 days - Newhaven Pharmacies Limited
28 days - Industry AVG
Creditor Days
its suppliers are paid after 96 days, this is slower than average (61 days)
96 days - Newhaven Pharmacies Limited
61 days - Industry AVG
Stock Days
it holds stock equivalent to 140 days, this is more than average (34 days)
140 days - Newhaven Pharmacies Limited
34 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 0 weeks, this is less cash available to meet short term requirements (11 weeks)
0 weeks - Newhaven Pharmacies Limited
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 47.6%, this is a lower level of debt than the average (59.8%)
47.6% - Newhaven Pharmacies Limited
59.8% - Industry AVG
NEWHAVEN PHARMACIES LIMITED financials
EXPORT
Newhaven Pharmacies Limited's latest turnover from September 2024 is estimated at £1.9 million and the company has net assets of £809.9 thousand. According to their latest financial statements, Newhaven Pharmacies Limited has 11 employees and maintains cash reserves of £7.3 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Sep 2024
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Turnover
1,851,893
1,468,753
1,199,570
1,626,563
1,625,296
1,138,238
1,246,712
1,324,897
1,421,546
1,131,459
6,130,613
5,141,362
4,344,608
5,112,916
4,942,731
Other Income Or Grants
Cost Of Sales
1,269,296
992,238
795,493
1,095,445
1,117,826
782,209
843,810
897,964
983,038
789,666
4,243,902
3,577,384
3,071,456
3,596,202
3,438,403
Gross Profit
582,597
476,516
404,077
531,117
507,471
356,029
402,902
426,932
438,508
341,793
1,886,711
1,563,978
1,273,152
1,516,713
1,504,328
Admin Expenses
336,061
164,238
337,174
472,562
444,395
480,088
460,847
498,367
384,691
490,601
2,002,422
1,679,633
1,326,638
1,518,927
305,253
Operating Profit
246,536
312,278
66,903
58,555
63,076
-124,059
-57,945
-71,435
53,817
-148,808
-115,711
-115,655
-53,486
-2,214
1,199,075
Interest Payable
69
35
4
1,528
2,447
1,021
Interest Receivable
1,963
1,952
65
28
66
658
314
251
444
12
1
2
2
1
Pre-Tax Profit
248,429
314,195
66,964
57,056
60,694
-124,422
-57,631
-71,184
54,261
-148,796
-115,710
-115,653
-53,484
-2,213
1,199,075
Tax
-62,107
-78,549
-12,723
-10,841
-11,532
-10,852
-335,741
Profit After Tax
186,322
235,646
54,241
46,215
49,162
-124,422
-57,631
-71,184
43,409
-148,796
-115,710
-115,653
-53,484
-2,213
863,334
Dividends Paid
Retained Profit
186,322
235,646
54,241
46,215
49,162
-124,422
-57,631
-71,184
43,409
-148,796
-115,710
-115,653
-53,484
-2,213
863,334
Employee Costs
319,062
283,784
242,185
317,797
298,254
285,946
331,044
334,291
331,117
173,307
895,844
708,781
553,984
659,273
603,844
Number Of Employees
11
11
10
14
14
13
17
18
19
10
52
42
33
39
36
EBITDA*
246,536
317,634
69,734
61,886
70,516
-117,114
-49,241
-67,830
59,515
-142,885
-111,128
-109,219
-47,398
4,156
1,207,404
* Earnings Before Interest, Tax, Depreciation and Amortisation
Sep 2024
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Tangible Assets
13,638
18,994
21,825
25,156
29,646
210,255
185,685
182,133
82,240
81,055
85,638
91,500
97,259
102,555
Intangible Assets
6,530
6,530
6,530
Investments & Other
6,530
6,530
6,530
6,530
6,530
6,530
Debtors (Due After 1 year)
Total Fixed Assets
13,638
18,994
21,825
25,156
29,646
216,785
192,215
188,663
88,770
87,585
92,168
98,030
103,789
109,085
Stock & work in progress
490,236
302,400
149,550
120,524
101,350
50,397
82,930
117,745
114,778
113,426
127,433
159,184
168,831
159,552
167,137
Trade Debtors
108,463
101,226
106,848
185,248
225,447
124,155
114,767
124,986
140,255
125,651
1,158,490
1,124,621
1,029,037
1,062,610
1,019,650
Group Debtors
923,378
892,743
648,732
532,863
214,299
743,228
Misc Debtors
17,218
20,341
18,060
50,678
19,843
55,213
854,591
1,035,149
873,009
917,828
Cash
7,303
71,214
3,136
2,652
53,373
77,934
97,540
27,896
173,025
4,499
298
140
641
160
160
misc current assets
total current assets
1,546,598
1,387,924
926,326
891,965
614,312
1,050,927
1,149,828
1,305,776
1,301,067
1,161,404
1,286,221
1,283,945
1,198,509
1,222,322
1,186,947
total assets
1,546,598
1,401,562
945,320
913,790
639,468
1,080,573
1,366,613
1,497,991
1,489,730
1,250,174
1,373,806
1,376,113
1,296,539
1,326,111
1,296,032
Bank overdraft
632
630
92
30,245
Bank loan
Trade Creditors
336,462
296,769
227,667
240,640
286,594
213,370
222,876
256,292
278,141
280,629
772,597
658,863
462,969
438,362
405,607
Group/Directors Accounts
246,816
245,116
253,051
140,235
573,934
736,799
732,040
645,920
443,887
other short term finances
50,000
hp & lease commitments
other current liabilities
152,833
235,514
76,715
199,177
15,443
24,755
44,247
89,337
74,163
74,029
total current liabilities
736,743
778,029
557,433
580,144
352,037
842,304
1,003,922
1,077,669
998,224
798,545
772,597
658,863
462,969
438,362
405,607
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
615
778
1,277
1,850
2,191
total long term liabilities
615
778
1,277
1,850
2,191
total liabilities
736,743
778,029
557,433
580,144
352,037
842,304
1,003,922
1,077,669
998,224
798,545
773,212
659,641
464,246
440,212
407,798
net assets
809,855
623,533
387,887
333,646
287,431
238,269
362,691
420,322
491,506
451,629
600,594
716,472
832,293
885,899
888,234
total shareholders funds
809,855
623,533
387,887
333,646
287,431
238,269
362,691
420,322
491,506
451,629
600,594
716,472
832,293
885,899
888,234
Sep 2024
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Operating Activities
Operating Profit
246,536
312,278
66,903
58,555
63,076
-124,059
-57,945
-71,435
53,817
-148,808
-115,711
-115,655
-53,486
-2,214
1,199,075
Depreciation
5,356
2,831
3,331
7,440
6,945
8,704
3,605
5,698
5,923
4,583
6,436
6,088
6,370
8,329
Amortisation
Tax
-62,107
-78,549
-12,723
-10,841
-11,532
-10,852
-335,741
Stock
187,836
152,850
29,026
19,174
50,953
-32,533
-34,815
2,967
1,352
-14,007
-31,751
-9,647
9,279
-7,585
167,137
Debtors
34,749
240,670
4,851
309,200
-463,007
-46,762
-190,777
146,871
-30,215
-115,011
33,869
95,584
-33,573
42,960
1,019,650
Creditors
39,693
69,102
-12,973
-45,954
73,224
-9,506
-33,416
-21,849
-2,488
-491,968
113,734
195,894
24,607
32,755
405,607
Accruals and Deferred Income
-82,681
158,799
-122,462
183,734
-9,312
-19,492
-45,090
15,174
134
74,029
Deferred Taxes & Provisions
-615
-163
-499
-573
-341
2,191
Cash flow from operations
-81,144
73,466
-112,301
-139,549
534,950
-66,817
97,845
-224,343
75,172
-432,421
325
239
930
1,195
92,674
Investing Activities
capital expenditure
13,638
-2,950
180,194
-33,274
-7,157
-112,121
-7,108
-574
-329
-1,074
-110,884
Change in Investments
-6,530
6,530
cash flow from investments
13,638
-2,950
180,194
-33,274
-7,157
-105,591
-7,108
-574
-329
-1,074
-117,414
Financing Activities
Bank loans
Group/Directors Accounts
1,700
-7,935
112,816
140,235
-573,934
-162,865
4,759
86,120
202,033
443,887
Other Short Term Loans
-50,000
50,000
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
-3,532
-169
-168
-168
-122
-122
24,900
interest
1,894
1,917
61
-1,500
-2,381
-363
314
251
444
12
1
2
2
1
cash flow from financing
3,594
-6,018
112,877
88,735
-526,315
-163,228
5,073
86,371
198,945
443,730
-167
-166
-120
-121
24,900
cash and cash equivalents
cash
-63,911
68,078
484
-50,721
-24,561
-19,606
69,644
-145,129
168,526
4,201
158
-501
481
160
overdraft
2
630
-92
92
-30,245
30,245
change in cash
-63,913
67,448
576
-50,813
5,684
-49,851
69,644
-145,129
168,526
4,201
158
-501
481
160
newhaven pharmacies limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for newhaven pharmacies limited. Get real-time insights into newhaven pharmacies limited's credit score, group structure and payment trends.
Perform a competitor analysis for newhaven pharmacies limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in EC1V area or any other competitors across 12 key performance metrics.
newhaven pharmacies limited Ownership
NEWHAVEN PHARMACIES LIMITED group structure
Newhaven Pharmacies Limited has no subsidiary companies.
The sole shareholder of Newhaven Pharmacies Limited is Allcures Plc.
allcures plc
100%
newhaven pharmacies limited directors
Newhaven Pharmacies Limited currently has 3 directors.
The longest serving directors include
Mr Jagdeesh Cheema (Aug 2019) and
Mr Jagdeesh Cheema (Aug 2019).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 10 charges/mortgages relating to newhaven pharmacies limited. Currently there are 6 open charges and 4 have been satisfied in the past.
newhaven pharmacies limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NEWHAVEN PHARMACIES LIMITED. This can take several minutes, an email will notify you when this has completed.
newhaven pharmacies limitedCompanies House Filings - See Documents
